News | July 24, 2021
Lonza reports strong momentum in H1 2021
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Oxygen Park is a concept where a two-layer layout is being used to plant oxygen releasing trees which releases oxygen for 24 hours
Subscribe To Our Newsletter & Stay Updated
